Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Relay Therapeutics (NASDAQ:RLAY) outlined new data and development plans for its lead oncology program, zovegalisib, during a “frontline breast cancer update” conference call, highlighting encouraging ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer (NYSE:PFE) used its 2026 annual meeting of shareholders to highlight recent operational performance, outline strategic ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Lyme disease is the most common tick-borne infectious disease in the United States. Named for the Connecticut town where it was first reported in the 1970s, Lyme is prevalent in the northeast and ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

April 24 (Reuters) - Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood ...

AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February.

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...